Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06962111 · ClinicalTrials.gov registry record · NA

Early-Stage Partner in Care Living Alone Plus

A NA study of Alzheimer Disease and Dementia, sponsored by Arizona State University.

Recruiting
Registry status
NA
Development phase
70
Enrollment target
1
Study location

NCT06962111 is a NA study of Alzheimer Disease and Dementia that is actively recruiting participants, run by Arizona State University. The registered enrollment target is 70 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06962111, a NA study of Alzheimer Disease and Dementia, is actively recruiting participants, sponsored by Arizona State University.

RECRUITING
Registry status
NA
Development phase
70 participants
Enrollment target
1
Study location

Study Summary

EPICLA+ (Early-Stage Partners in Care Living Alone Plus) is a research project designed to assist people with early-stage memory loss who live alone in the community by providing early-stage related education and skill-training sessions, held via Zoom, designed to reduce stress, enhance well-being, manage challenges, and plan for the future. Researchers will gather feedback from individuals about their experience to continue to improve programs for early-stage memory loss.

Interventions

  • BEHAVIORAL Psychoeducational skills training intervention

Study Locations (1)

Arizona

  • Arizona State University - Phoenix

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2025-03-26
Est. Completion 2027-03
Phase NA

Sponsor

Arizona State University

187 total trials

What the Registry Record Tells You About NCT06962111

The ClinicalTrials.gov registry entry for NCT06962111 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (97% lower). The listed sponsor is Arizona State University, which has 187 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which Psychoeducational skills training intervention is the first listed.

NCT06962111 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.

Frequently Asked Questions

What is clinical trial NCT06962111 about?

NCT06962111 is a clinical study titled "Early-Stage Partner in Care Living Alone Plus". EPICLA+ (Early-Stage Partners in Care Living Alone Plus) is a research project designed to assist people with early-stage memory loss who live alone in the community by providing early-stage related education and skill-training sessions, held via Zoom, designed to reduce stress, enhance well-being, ...

What is the current status of trial NCT06962111?

This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2025-03-26. Estimated completion is 2027-03.

What conditions does trial NCT06962111 study?

This clinical trial studies the following conditions: Alzheimer Disease, Dementia, Mild Cognitive Impairment (MCI).

What interventions are being tested in trial NCT06962111?

The interventions under investigation include: Psychoeducational skills training intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT06962111?

This trial is sponsored by Arizona State University, which has 187 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06962111 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.